Anti-Brn-3a Antibody, clone 5A3.2 ZooMAb® Mouse Monoclonal

Кат. номер

ZMS1050-4X25UL

ZMS1050-25UL

ZooMAb® antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb® antibodies are reliably available and ready to ship when you need them.
Specificity
Clone 5A3.2 is a ZooMAb® Mouse recombinant monoclonal antibody that specifically detects Brn-3a. It targets an epitope within 39 amino acids from the internal region.
Recombinant fusion protein fragment corresponding to 39 amino acids from the internal region of human Brn-3a.
Quality Control Testing
Evaluated by Western Blotting with recombinant human in Brn-3a.
Western Blotting Analysis: A 1:10,000 dilution of this antibody detected recombinant human Brn-3a.
Tested applications
ELISA Analysis: 300 µg/mL from a representative lot detected recombinant human Brn-3a.
Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected Brn-3a in human retina tissue sections.
Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user
Anti-Brn-3a, clone 5A3.2 ZooMAb®, Cat. No. ZMS1050, is a recombinant Mouse monoclonal antibody that detects Brn-3a and is tested for use in ELISA, Immunohistochemistry (Paraffin), and Western Blotting.
Target description
POU domain, class 4, transcription factor 1 (UniProt: Q01851; also known as Brain-specific homeobox/POU domain protein 3A, Brain-3A, Brn-3A, Homeobox/POU domain protein RDC-1, Oct-T1) is encoded by the POU4F1 (also known as BRN3A, RDC1) gene (Gene ID: 5457) in human. Brn-3a is a multifunctional transcription factor that is expressed in the brain and the retina and is present in the developing brain, spinal cord, and eye. Its C-terminal domain is able to act as both DNA-binding domain and a transcriptional activator. Its N-terminal domain is shown to be essential for its transactivation activity on some target genes. Brn-3a also activates Bcl-2 expression and protects neuronal cells from apoptosis. It regulates the expression of specific genes involved in differentiation and survival within a subset of neuronal lineages. It has been reported that neurite outgrowth and expression of genes required for synapse formation are primarily dependent on the C-terminal domain, however the N-terminal domain is required for maximal induction. Two isoforms of Brn-3a have been described that are produced by alternative splicing. Isoform 1 is shown to interact with Brn-3b (POU4F2) and this interaction inhibits both DNA-binding and transcriptional activities of Brn3a. Isoform 2 that lacks amino acids 1-84 can act as transcription factor but cannot regulate the expression of the same subset of genes and does not have antiapoptotic effects on neuronal cells. This ZooMAb® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.
Physical form
Purified recombinant mouse monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb® formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.
Reconstitution
300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
Storage and Stability
Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Quality Level	200
biological source	mouse
recombinant	expressed in HEK 293 cells
antibody form	purified antibody
antibody product type	primary antibodies
clone	5A3.2, recombinant monoclonal
description	recombinant, expressed in HEK 293 cells
product line	ZooMAb®
form	lyophilized
mol wt	calculated mol wt 42.7 kDa","observed mol wt ~50 kDa
purified by	using Protein A
species reactivity	human
species reactivity (predicted by homology)	rat, chicken
packaging	antibody small pack of 25 µL
enhanced validation	recombinant expression
application(s)	ELISA: suitable","immunohistochemistry (formalin-fixed, paraffin-embedded sections): suitable","western blot: suitable
isotype	IgG1
epitope sequence	Internal
conjugate	unconjugated
UniProt accession no.	Q01851,
shipped in	ambient
storage temp.	2-8°C